Is the price fair?
What AUPH's price assumes
Aurinia Pharmaceuticals Inc. trades at 7.62× earnings against 32.4× for the median Biotechnology name, cheaper than its own group.
7.62
Trailing P/E · Biotechnology median 32.4 · cheaper than the typical name in its group
- Price / sales
- 6.84
Price / sales · as of 2026-Q1
- Price / book
- 3.59
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 3.59
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Market capitalisation
- $2.12B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.